- Home
- SBR vs ORIC Comparison
SBR vs ORIC Comparison
Compare SBR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- ORIC
- Stock Information
- Founded
- SBR 1982
- ORIC 2014
- Country
- SBR United States
- ORIC United States
- Employees
- SBR N/A
- ORIC N/A
- Industry
- SBR Oil & Gas Production
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- SBR Energy
- ORIC Health Care
- Exchange
- SBR Nasdaq
- ORIC Nasdaq
- Market Cap
- SBR 1.1B
- ORIC 974.1M
- IPO Year
- SBR N/A
- ORIC 2020
- Fundamental
- Price
- SBR $76.61
- ORIC $10.90
- Analyst Decision
- SBR
- ORIC Strong Buy
- Analyst Count
- SBR 0
- ORIC 10
- Target Price
- SBR N/A
- ORIC $17.33
- AVG Volume (30 Days)
- SBR 47.6K
- ORIC 895.7K
- Earning Date
- SBR 01-01-0001
- ORIC 11-11-2025
- Dividend Yield
- SBR 7.16%
- ORIC N/A
- EPS Growth
- SBR N/A
- ORIC N/A
- EPS
- SBR 5.05
- ORIC N/A
- Revenue
- SBR $77,682,730.00
- ORIC N/A
- Revenue This Year
- SBR N/A
- ORIC N/A
- Revenue Next Year
- SBR N/A
- ORIC N/A
- P/E Ratio
- SBR $15.22
- ORIC N/A
- Revenue Growth
- SBR N/A
- ORIC N/A
- 52 Week Low
- SBR $58.25
- ORIC $3.90
- 52 Week High
- SBR $77.49
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- SBR 65.94
- ORIC 58.48
- Support Level
- SBR $73.56
- ORIC $10.36
- Resistance Level
- SBR $76.52
- ORIC $11.16
- Average True Range (ATR)
- SBR 1.37
- ORIC 0.51
- MACD
- SBR 0.06
- ORIC 0.06
- Stochastic Oscillator
- SBR 85.35
- ORIC 74.31
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.